Silence Therapeutics PLC (SLN) FinancialsSLNSilence Therapeutics PLC

Evaluating the bottom line, Silence Therapeutics PLC maintains a gross margin of 97.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7014.69%, while the net margin is -6451.42%. These profitability ratios, combined with a Return on Equity (ROE) of -90.41%, provide a clear picture of how effectively SLN converts its operational activities into shareholder value.

In the context of the broader market, SLN competes directly with industry leaders such as LINC and OCS. With a market capitalization of $809.82M, it holds a significant position in the sector. When comparing efficiency, SLN's gross margin of 97.39% stands against LINC's 58.17% and OCS's N/A. Such benchmarking helps identify whether Silence Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Silence Therapeutics reported a narrowed net loss of $12.68 million in Q2 2026, down from $27.4 million a year earlier, indicating improved financial health. The gross margin for Q1 2026 was a strong 97.39%, suggesting efficient cost management in operations.